Edition:
United States

Mesoblast Ltd (MSB.AX)

MSB.AX on Australia Stock Exchange

1.94AUD
21 Jul 2017
Change (% chg)

$-0.05 (-2.76%)
Prev Close
$2.00
Open
$2.00
Day's High
$2.00
Day's Low
$1.87
Volume
1,152,107
Avg. Vol
959,930
52-wk High
$3.44
52-wk Low
$1.07

MSB.AX

Chart for MSB.AX

About

Mesoblast Limited is engaged in developing cell-based medicines. The Company has leveraged its technology platform, which is based on specialized cells known as mesenchymal lineage adult stem cells, to establish a portfolio of late-stage product candidates. Its allogeneic, off-the-shelf cell product candidates target advanced... (more)

Overall

Beta: 1.61
Market Cap(Mil.): $842.45
Shares Outstanding(Mil.): 434.25
Dividend: --
Yield (%): --

Financials

  MSB.AX Industry Sector
P/E (TTM): -- 213.75 15.85
EPS (TTM): -0.00 -- --
ROI: -0.19 -7.93 -8.31
ROE: -0.26 -9.29 -7.95

BRIEF-Mesoblast Ltd files ‍​for $180 million American depositary shares representing ordinary shares

* Mesoblast Ltd - files ‍​for $180 million American depositary shares representing ordinary shares Source text: (http://bit.ly/2u50ziE) Further company coverage:

Jul 10 2017

UPDATE 1-Australia's Mesoblast posts narrower quarterly loss, rise in R&D costs

May 25 Australian regenerative medicine maker Mesoblast Ltd on Thursday posted a narrower quarterly loss but booked a rise in research and development costs.

May 25 2017

CORRECTED-Australia's Mesoblast flags "going concern" doubts

May 25 Australian regenerative medicine maker Mesoblast Ltd said on Thursday it needed new funding from a third party partner or from capital raising to continue in business as it had cash reserves of $69.1 million.

May 25 2017

BRIEF-Mesoblast receives A$3.7m from Australian Government for research and development

* Asx alert-Mesoblast receives A$3.7m from AUS Government for research and development-MSB.AX Source text for Eikon: Further company coverage:

Apr 05 2017

BRIEF-FDA clears heart disease trial at Harvard's Boston Children's Hospital using Mesoblast's Cell Therapy

* FDA clears heart disease trial at Harvard's Boston Children's Hospital using Mesoblast's Cell Therapy to grow heart muscle in children with congenital heart disease Source text for Eikon: Further company coverage:

Apr 03 2017

BRIEF-IDMC starts interim analysis of Mesoblast's phase 3 heart failure trial

* Independent Data Monitoring Committee initiates process for interim analysis of Mesoblast’S phase 3 chronic heart failure trial

Mar 31 2017

BRIEF-Mesoblast updates on durable three year outcomes in disc disease

* Mesoblast says 36-month results from randomized, placebo-controlled 100- patient phase 2 trial of allogeneic mpcs in patients with chronic low back pain

Mar 14 2017

BRIEF-FDA grants fast track designation for Mesoblast's cell therapy in children with acute graft versus host disease

* FDA grants fast track designation for Mesoblast's cell therapy in children with acute graft versus host disease

Mar 07 2017

BRIEF-Mesoblast provides data from mid-stage trial on cell therapy MPC-300-IV

* Announced 39-week data from phase 2 trial in patients with rheumatoid arthritis resistant to anti-tumor necrosis factor agents

Feb 15 2017

Earnings vs. Estimates